The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline
Open accessAbstract
An evidence-based clinical guideline for the diagnosis and management of Paget's disease of bone (PDB) was developed using GRADE methodology, by a Guideline Development Group (GDG) led by the Paget's Association (UK). A systematic review of diagnostic tests and pharmacological and nonpharmacological treatment options was conducted that sought to address several key questions of clinical relevance. Twelve recommendations and five conditional recommendations were made, but there was insufficient evidence to address eight of the questions posed. The following recommendations were identified as the most important: 1) Radionuclide bone scans, in addition to targeted radiographs, are recommended as a means of fully and accurately defining the extent of metabolically active disease in patients with PDB. 2) Serum total alkaline phosphatase (ALP) is recommended as a first-line biochemical screening test in combination with liver function tests in screening for the presence of metabolically active PDB. 3) Bisphosphonates are recommended for the treatment of bone pain associated with PDB. Zoledronic acid is recommended as the bisphosphonate most likely to give a favorable pain response. 4) Treatment aimed at improving symptoms is recommended over a treat-to-target strategy aimed at normalizing total ALP in PDB. 5) Total hip or knee replacements are recommended for patients with PDB who develop osteoarthritis in whom medical treatment is inadequate. There is insufficient information to recommend one type of surgical approach over another. The guideline was endorsed by the European Calcified Tissues Society, the International Osteoporosis Foundation, the American Society of Bone and Mineral Research, the Bone Research Society (UK), and the British Geriatric Society. The GDG noted that there had been a lack of research on patient-focused clinical outcomes in PDB and identified several areas where further research was needed. © 2019 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Watts, G. D. J., Wymer, J., Kovach, M. J., Mehta, S. G., Mumm, S., Darvish, D., Pestronk, A., Whyte, M. P., & Kimonis, V. E. (2004) · Nature Genetics · doi:10.1038/ng1332 · Cited by 1,391 · cited 1×
“In some of these syndromes, PDB is part of a multisystem disorder accompanied by myopathy and neurodegeneration.((20,21))”
BackgroundAlonso-Coello, P., Schünemann, H. J., Moberg, J., Brignardello-Petersen, R., Akl, E. A., Davoli, M., Treweek, S., Mustafa, R. A., Rada, G., Rosenbaum, S., et al. (2016) · BMJ · doi:10.1136/bmj.i2016 · Cited by 1,317
Alonso-Coello, P., Oxman, A. D., Moberg, J., Brignardello-Petersen, R., Akl, E. A., Davoli, M., Treweek, S., Mustafa, R. A., Vandvik, P. O., Meerpohl, J., et al. (2016) · BMJ · doi:10.1136/bmj.i2089 · Cited by 814
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.
Laurin, N., Brown, J. P., Morissette, J., & Raymond, V. (2002) · The American Journal of Human Genetics · doi:10.1086/340731 · Cited by 563 · cited 2×
“(8–10) The most important susceptibility gene for PDB is SQSTM1,(11,12) which encodes p62, a protein involved in the nuclear factor kappa B (NF-kB) signaling pathway.”
BackgroundDomain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s disease.
Hocking, L. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.22.2735 · Cited by 350 · cited 2×
“(8–10) The most important susceptibility gene for PDB is SQSTM1,(11,12) which encodes p62, a protein involved in the nuclear factor kappa B (NF-kB) signaling pathway.”
BackgroundHocking, L. J., Lucas, G. J., Daroszewska, A., Cundy, T., Nicholson, G. C., Donath, J., Walsh, J. P., Finlayson, C., Cavey, J. R., Ciani, B., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0403015 · Cited by 156
Self-citation
Research works printed but not linked: 125
- Davie, 1999, Paget's disease of bone: a review of 889 patients, Bone, 24, 11S, 10.1016/S8756-3282(99)00027-7 · DOI
- van Staa, 2002, Incidence and natural history of Paget's disease of bone in England and Wales, J Bone Miner Res, 17, 465, 10.1359/jbmr.2002.17.3.465 · DOI · Paper page
- Corral-Gudino, 2013, Epidemiology of Paget's disease of bone: a systematic review and meta-analysis of secular changes, Bone, 55, 347, 10.1016/j.bone.2013.04.024 · DOI
- Mays, 2010, Archaeological skeletons support a northwest European origin for Paget's disease of bone, J Bone Miner Res, 25, 1839, 10.1002/jbmr.64 · DOI
- Meunier, 1980, Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue, Arthritis Rheum, 23, 1095, 10.1002/art.1780231005 · DOI · Paper page
- Sofaer, 1983, A family study of Paget's disease of bone, J Epidemiol Community Health, 37, 226, 10.1136/jech.37.3.226 · DOI
- Siris, 1991, Familial aggregation of Paget's disease of bone, J Bone Miner Res, 6, 495, 10.1002/jbmr.5650060511 · DOI · Paper page
- Morales-Piga, 1995, Frequency and characteristics of familial aggregation of Paget's disease of bone, J Bone Miner Res, 10, 663, 10.1002/jbmr.5650100421 · DOI · Paper page
- Morissette, 2006, Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone, J Bone Miner Res, 38, 10.1359/jbmr.06s207 · DOI
- Hocking, 2000, Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q, Bone, 26, 577, 10.1016/S8756-3282(00)00278-7 · DOI
- Moscat, 2009, p62 at the crossroads of autophagy, apoptosis, and cancer, Cell, 137, 1001, 10.1016/j.cell.2009.05.023 · DOI · Paper page
- Beyens, 2004, Evaluation of the role of the SQSTM1 gene in sporadic Belgian patients with Paget's disease, Calcif Tissue Int, 75, 144, 10.1007/s00223-004-0244-4 · DOI
- Jin, 2008, Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice, J Clin Invest, 118, 1858, 10.1172/JCI34257 · DOI · Paper page
- Hughes, 2000, Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis, Nat Genet, 24, 45, 10.1038/71667 · DOI · Paper page
- Whyte, 2002, Osteoprotegerin deficiency and juvenile Paget's disease, N Engl J Med, 347, 175, 10.1056/NEJMoa013096 · DOI · Paper page
- Divisato, 2016, ZNF687 mutations in severe Paget disease of bone associated with giant cell tumor, Am J Hum Genet, 98, 275, 10.1016/j.ajhg.2015.12.016 · DOI
- Kim, 2013, Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS, Nature, 495, 467, 10.1038/nature11922 · DOI · Paper page
- Albagha, 2011, Genome-wide association identifies three new susceptibility loci for Paget's disease of bone, Nat Genet, 43, 685, 10.1038/ng.845 · DOI · Paper page
- Bolland, 2007, Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations, J Bone Miner Res, 22, 411, 10.1359/jbmr.061204 · DOI
- Cundy, 2004, Paget's disease of bone in New Zealand: continued decline in disease severity, Calcif Tissue Int, 75, 358, 10.1007/s00223-004-0281-z · DOI
- Doyle, 2002, Paget's disease in New Zealand: evidence for declining prevalence, Bone, 31, 616, 10.1016/S8756-3282(02)00876-1 · DOI
- Poor, 2006, Epidemiology of Paget's disease in Europe: the prevalence is decreasing, J Bone Miner Res, 21, 1545, 10.1359/jbmr.060704 · DOI
- Corral-Gudino, 2013, Secular changes in Paget's disease: contrasting changes in the number of new referrals and in disease severity in two neighboring regions of Spain, Osteoporos Int, 24, 443, 10.1007/s00198-012-1954-5 · DOI
- Cooper, 1999, The epidemiology of Paget's disease in Britain: is the prevalence decreasing, J Bone Miner Res, 14, 192, 10.1359/jbmr.1999.14.2.192 · DOI · Paper page
- Britton, 2017, The changing presentation of Paget's disease of bone in Australia, a high prevalence region, Calcif Tissue Int, 101, 564, 10.1007/s00223-017-0312-1 · DOI
- Mangham, 2009, Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation, Bone, 44, 431, 10.1016/j.bone.2008.11.002 · DOI
- Siris, 1994, Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions, Semin Arth Rheum, 23, 222, 10.1016/0049-0172(94)90037-X · DOI
- Lever, 2002, Paget's disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: a speculative hypothesis, Bone, 31, 434, 10.1016/S8756-3282(02)00833-5 · DOI
- Solomon, 1979, Billiard-player's fingers: an unusual case of Paget's disease of bone, Br Med J, 1, 931, 10.1136/bmj.1.6168.931 · DOI
- Hamdy, 1979, Trauma and Paget's disease of bone, Br Med J, 1, 1487, 10.1136/bmj.1.6176.1487-b · doi:10.1136/bmj.1.6176.1487-b
- Rebel, 1974, Ultrastructural characteristics of osteoclasts in Paget's disease, Rev Rhum Mal Osteoartic, 41, 767
- Mills, 1984, Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone, Clin Orthop Rel Res, 183, 303, 10.1097/00003086-198403000-00044 · DOI · Paper page
- O'Driscoll, 1985, Past pets and Paget's disease, Lancet, 2, 919, 10.1016/S0140-6736(85)90852-9 · DOI
- Teramachi, 2016, Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease, J Clin Invest, 126, 1012, 10.1172/JCI82012 · DOI
- Matthews, 2008, Failure to detect measles virus RNA in bone cells from patients with Paget's disease, J Clin Endocrinol Metab, 93, 1398, 10.1210/jc.2007-1978 · DOI
- Ralston, 1991, Failure to detect paramyxovirus sequences in Paget's disease of bone using the polymerase chain reaction, J Bone Miner Res, 6, 1243, 10.1002/jbmr.5650061115 · DOI
- Ralston, 2007, Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget's disease of bone, J Bone Miner Res, 22, 569, 10.1359/jbmr.070103 · DOI
- Helfrich, 2000, A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients, J Bone Miner Res, 15, 2315, 10.1359/jbmr.2000.15.12.2315 · DOI
- Gordon, 1992, Canine distemper transcripts sequenced from pagetic bone, Bone Miner, 19, 159, 10.1016/0169-6009(92)90923-2 · DOI
- Reddy, 1996, Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease, J Bone Miner Res, 11, 1602, 10.1002/jbmr.5650111103 · DOI
- Ooi, 2000, Absence of measles virus and canine distemper virus transcripts in long- term bone marrow cultures from patients with Paget's disease of bone, Bone, 27, 417, 10.1016/S8756-3282(00)00343-4 · DOI
- Birch, 1994, Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bone, J Bone Miner Res, 9, 11, 10.1002/jbmr.5650090103 · DOI
- Visconti, 2017, Antibody response to paramyxoviruses in Paget's disease of bone, Calcif Tissue Int, 101, 141, 10.1007/s00223-017-0265-4 · DOI
- Helfrich, 2014, Genetics and aetiology of Pagetic disorders of Bone, Arch Biochem Biophys, 473, 172, 10.1016/j.abb.2008.02.045 · DOI
- Douglas, 1981, Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis, J Bone Joint Surg Br, 63B, 495, 10.1302/0301-620X.63B4.6457839 · DOI
- Tuck, 2017, Adult Paget's disease of bone: a review, Rheumatology (Oxford), 56, 2050, 10.1093/rheumatology/kew430 · DOI
- Tan, 2014, Clinical presentation of Paget's disease: evaluation of a contemporary cohort and systematic review, Calcif Tissue Int, 95, 385, 10.1007/s00223-014-9904-1 · DOI
- Reid, 1996, Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial, Am J Med, 101, 341, 10.1016/S0002-9343(96)00227-6 · DOI · Paper page
- Langston, 2010, Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone, J Bone Miner Res, 25, 20, 10.1359/jbmr.090709 · DOI · Paper page
- Ruggieri, 2010, The role of surgery and adjuvants to survival in Pagetic osteosarcoma, Clin Orthop Relat Res, 468, 2962, 10.1007/s11999-010-1473-7 · DOI
- Rendina, 2015, Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone, J Bone Miner Res, 30, 257, 10.1002/jbmr.2349 · DOI
- Divisato, 2016, ZNF687 mutations in severe Paget disease of bone associated with giant cell tumor, Am J Hum Genet, 98, 275, 10.1016/j.ajhg.2015.12.016 · DOI
- Selby, 2002, Guidelines on the management of Paget's disease of bone, Bone, 31, 366, 10.1016/S8756-3282(02)00817-7 · DOI · Paper page
- Takata, 2006, Guidelines for diagnosis and management of Paget's disease of bone in Japan, J Bone Miner Metab, 24, 359, 10.1007/s00774-006-0696-x · DOI
- Singer, 2014, Paget's disease of bone: an endocrine society clinical practice guideline, J Clin Endocrinol Metab, 99, 4408, 10.1210/jc.2014-2910 · DOI · Paper page
- Ralston, 2013, Clinical practice, Paget's disease of bone. N Engl J Med, 368, 644
- Hsu, 2011, Application of GRADE: making evidence-based recommendations about diagnostic tests in clinical practice guidelines, Implement Sci, 6, 62, 10.1186/1748-5908-6-62 · DOI
- Corral-Gudino, 2017, Bisphosphonates for Paget's disease of bone in adults, Cochrane Database Syst Rev, 12, CD004956
- Brouwers, 2016, The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines, BMJ, 352, i1152, 10.1136/bmj.i1152 · DOI · Paper page
- Eekhoff, 2004, Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey—the Rotterdam Study, J Bone Miner Res, 19, 566, 10.1359/jbmr.2004.19.4.566 · DOI
- Mirra, 1995, Paget's disease of bone: review with emphasis on radiologic features, Part II. Skeletal Radiol, 24, 173
- Guanabens, 2012, Implications of a new radiological approach for the assessment of Paget disease, Calcif Tissue Int, 91, 409, 10.1007/s00223-012-9652-z · doi:10.1007/s00223-012-9652-z
- Shirazi, 1974, Bone scanning in evaluation of Paget's disease of bone, CRC Crit Rev Clin Radiol Nucl Med, 5, 523
- Kim, 1997, The ‘mouse face’ appearance of the vertebrae in Paget's disease, Clin Nucl Med, 22, 104, 10.1097/00003072-199702000-00007 · doi:10.1097/00003072-199702000-00007
- Rotes-Sala, 2004, The clover and heart signs in vertebral scintigraphic images are highly specific of Paget's disease of bone, Bone, 34, 605, 10.1016/j.bone.2003.10.014 · doi:10.1016/j.bone.2003.10.014
- Reyes, 2008, Vertebral “clover” scintigraphic image in a vertebral metastasis misdiagnosed with Paget's disease, Clin Rheumatol, 27, 1585, 10.1007/s10067-008-1001-2 · doi:10.1007/s10067-008-1001-2
- Wellman, 1977, Skeletal scintimaging and radiography in the diagnosis and management of Paget's disease, Clin Orthop Relat Res, 127, 55
- Meunier, 1987, Skeletal distribution and biochemical parameters of Paget's disease, Clin Orthop Relat Res, 217, 37, 10.1097/00003086-198704000-00006 · DOI
- Fogelman, 1980, A comparison of bone scanning and radiology in the assessment of patients with symptomatic Paget's disease, Eur J Nucl Med, 5, 417, 10.1007/BF00261784 · doi:10.1007/bf00261784
- Roberts, 1989, Paget disease: MR imaging findings, Radiology, 173, 341, 10.1148/radiology.173.2.2798865 · doi:10.1148/radiology.173.2.2798865
- Tehranzadeh, 1998, Computed tomography of Paget disease of the skull versus fibrous dysplasia, Skeletal Radiol, 27, 664, 10.1007/s002560050456 · doi:10.1007/s002560050456
- Alvarez, 1997, Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity, Arthritis Rheum, 40, 461, 10.1002/art.1780400312 · DOI
- Alvarez, 1995, Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease, J Bone Miner Res, 10, 458, 10.1002/jbmr.5650100318 · doi:10.1002/jbmr.5650100318
- Woitge, 1999, Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices, J Bone Miner Res, 14, 792, 10.1359/jbmr.1999.14.5.792 · DOI · Paper page
- Al Nofal, 2015, Bone turnover markers in Paget's disease of the bone: a systematic review and meta-analysis, Osteoporos Int, 26, 1875, 10.1007/s00198-015-3095-0 · DOI
- Langston, 2007, Clinical determinants of quality of life in Paget's disease of bone, Calcif Tissue Int, 80, 1, 10.1007/s00223-006-0184-2 · DOI
- Condon, 1971, Glucagon in the treatment of Paget's disease of bone, Br Med J, 4, 719, 10.1136/bmj.4.5789.719 · doi:10.1136/bmj.4.5789.719
- Heath, 1981, The role of mithramycin in the management of Paget's disease, Metab Bone Dis Relat Res, 3, 343, 10.1016/0221-8747(81)90051-5 · doi:10.1016/0221-8747(81)90051-5
- Fennelly, 1971, Effect of actinomycin D on Paget's disease of bone, Br Med J, 1, 423, 10.1136/bmj.1.5746.423 · doi:10.1136/bmj.1.5746.423
- Bockman, 1995, A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone, J Clin Endocrinol Metab, 80, 595
- Reid, 2016, Treatment of Paget's disease of bone with denosumab: case report and literature review, Calcif Tissue Int, 99, 322, 10.1007/s00223-016-0150-6 · DOI
- Kanis, 1975, Treatment of Paget's disease of bone with porcine calcitonin: clinical and metabolic responses, Q J Med, 44, 399
- Ralston, 1987, The effect of one alpha hydroxyvitamin D3 on the mineralisation defect in disodium etidronate treated Paget's disease—a double-blind randomized study, J Bone Miner Res, 2, 5, 10.1002/jbmr.5650020103 · DOI
- Altman, 1973, Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans), N Engl J Med, 289, 1379, 10.1056/NEJM197312272892601 · DOI · Paper page
- Canfield, 1977, Diphosphonate therapy of Paget's disease of bone, J Clin Endocrinol Metab, 44, 96, 10.1210/jcem-44-1-96 · DOI · Paper page
- Fraser, 1997, A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone, Postgrad Med J, 73, 496, 10.1136/pgmj.73.862.496 · DOI
- McClung, 1995, Tiludronate therapy for Paget's disease of bone [published erratum appears in Bone 1996 Mar;18(3):292], Bone, 17, 493S, 10.1016/8756-3282(95)00282-1 · doi:10.1016/8756-3282(95)00282-1
- Reginster, 1992, Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study, Arthritis Rheumatism, 35, 967, 10.1002/art.1780350819 · doi:10.1002/art.1780350819
- Merlotti, 2007, Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone, J Bone Miner Res, 22, 1510, 10.1359/jbmr.070704 · DOI
- Walsh, 2004, A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone, Bone, 34, 747, 10.1016/j.bone.2003.12.011 · doi:10.1016/j.bone.2003.12.011
- Reid, 2005, Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease, N Engl J Med, 353, 898, 10.1056/NEJMoa044241 · DOI · Paper page
- Reid, 2011, A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years, J Bone Miner Res, 26, 2261, 10.1002/jbmr.438 · DOI
- Monsell, 1995, Hearing loss in Paget's disease of bone: evidence of auditory nerve integrity, Am J Otol, 16, 27
- Donath, 2004, Effect of bisphosphonate treatment in patients with Paget's disease of the skull, Rheumatology (Oxford), 43, 89, 10.1093/rheumatology/keg477 · DOI
- Wegrzyn, 2010, Cementless total hip arthroplasty in Paget's disease of bone: a retrospective review, Int Orthop, 34, 1103, 10.1007/s00264-009-0853-7 · doi:10.1007/s00264-009-0853-7
- Gabel, 1991, Total knee arthroplasty for osteoarthrosis in patients who have Paget disease of bone at the knee, J Bone Joint Surg Am, 73, 739, 10.2106/00004623-199173050-00013 · doi:10.2106/00004623-199173050-00013
- Lee, 2005, Total knee arthroplasty in patients with Paget's disease of bone at the knee, J Arthroplasty, 20, 689, 10.1016/j.arth.2004.11.007 · doi:10.1016/j.arth.2004.11.007
- Jorge-Mora, 2016, Surgical treatment in spine Paget's disease: a systematic review, Eur J Orthop Surg Traumatol, 26, 27, 10.1007/s00590-015-1659-5 · doi:10.1007/s00590-015-1659-5
- Parvizi, 2003, Corrective osteotomy for deformity in Paget disease, J Bone Joint Surg Am, 85-A, 697, 10.2106/00004623-200304000-00017 · doi:10.2106/00004623-200304000-00017
- Bickerstaff, 1990, Improvement in the deformity of the face in Paget's disease treated with diphosphonates, J Bone Joint Surg Br, 72, 132, 10.1302/0301-620X.72B1.2137127 · doi:10.1302/0301-620x.72b1.2137127
- Chen, 1979, Neurologic disturbances in Paget disease of bone: response to calcitonin, Neurology, 29, 448, 10.1212/WNL.29.4.448 · doi:10.1212/wnl.29.4.448
- Miller, 1999, A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group, Am J Med, 106, 513, 10.1016/S0002-9343(99)00062-5 · DOI · Paper page
- Gutteridge, 1996, Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study, Bone, 19, 387, 10.1016/S8756-3282(96)00224-4 · doi:10.1016/s8756-3282(96)00224-4
- Siris, 1996, Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone, J Clin Endocrinol Metab, 81, 961
- Tan, 2017, Long-term randomized trial of intensive versus symptomatic management in Paget's disease of bone: the PRISM-EZ Study, J Bone Miner Res, 32, 1165, 10.1002/jbmr.3066 · DOI
- Reid, 2010, Characterization of and risk factors for the acute-phase response after zoledronic acid, J Clin Endocrinol Metab, 95, 4380, 10.1210/jc.2010-0597 · DOI · Paper page
- Merlotti, 2011, Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone, J Bone Miner Res, 26, 512, 10.1002/jbmr.237 · DOI
- Martin, 1977, Clinical, biochemical and histological observations on the effect of porcine calcitonin in Paget's disease of bone, Aust N Z J Med, 7, 36, 10.1111/j.1445-5994.1977.tb03354.x · DOI
- O'Donoghue, 1987, Biochemical response to combination of disodium etidronate with calcitonin in Paget's disease, Bone, 8, 219, 10.1016/8756-3282(87)90168-2 · doi:10.1016/8756-3282(87)90168-2
- Schwarz, 2012, Paget's disease of the bone after treatment with Denosumab: a case report, Bone, 50, 1023, 10.1016/j.bone.2012.01.020 · DOI
- Ueda, 2015, Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial, Ann Oncol, 26, 2149, 10.1093/annonc/mdv307 · doi:10.1093/annonc/mdv307
- Chawla, 2013, Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study, Lancet Oncol, 14, 901, 10.1016/S1470-2045(13)70277-8 · DOI · Paper page
- Thomas, 2010, Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study, Lancet Oncol, 11, 275, 10.1016/S1470-2045(10)70010-3 · DOI · Paper page
- Cosso, 2010, Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent, Clin Cases Miner Bone Metab, 7, 145
- Verma, 2016, giant cell tumor developing in Paget's disease of bone: a case report with review of literature, J Orthop Case Rep, 6, 103
- Tanaka, 2017, Anti-osteoclastic agent, denosumab, for a giant cell tumor of the bone with concurrent Paget's disease: a case report, Oncol Lett, 13, 2105, 10.3892/ol.2017.5693 · doi:10.3892/ol.2017.5693
- Boudreau, 1983, Observations on serial radionuclide blood-flow studies in Paget's disease: concise communication, J Nucl Med, 24, 880
- Nicholas, 1965, Fracture of the femur in patients with Paget's disease; results of treatment in twenty-three cases, J Bone Joint Surg Am, 47, 450, 10.2106/00004623-196547030-00002 · doi:10.2106/00004623-196547030-00002
- Verinder, 1979, The management of fractures in Paget's disease of bone, Injury, 10, 276, 10.1016/0020-1383(79)90043-3 · doi:10.1016/0020-1383(79)90043-3
- Grundy, 1970, Fractures of the femur in Paget's disease of bone. Their etiology and treatment, J Bone Joint Surg Br, 52, 252, 10.1302/0301-620X.52B2.252 · doi:10.1302/0301-620x.52b2.252
- Bradley, 1992, Outcome after fractures of the femur in Paget's disease, Aust N Z J Surg, 62, 39, 10.1111/j.1445-2197.1992.tb05352.x · doi:10.1111/j.1445-2197.1992.tb05352.x
- Bidner, 1989, Femoral fractures in Paget's disease, J Orthop Trauma, 3, 317, 10.1097/00005131-198912000-00011 · doi:10.1097/00005131-198912000-00011
- McDonald, 1987, Total hip arthroplasty in Paget's disease, A follow-up note. J Bone Joint Surg Am, 69, 766, 10.2106/00004623-198769050-00020 · doi:10.2106/00004623-198769050-00020
- Parvizi, 2002, Outcome of uncemented hip arthroplasty components in patients with Paget's disease, Clin Orthop Relat Res, 403, 127, 10.1097/00003086-200210000-00020 · doi:10.1097/00003086-200210000-00020
- Roper, 1971, Paget's disease at the hip with osteoarthrosis: results of intertrochanteric osteotomy, J Bone Joint Surg Br, 53, 660, 10.1302/0301-620X.53B4.660 · doi:10.1302/0301-620x.53b4.660
Cited by
Bone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaca, T., Gossiel, F., Salam, S., & Eastell, R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 387
Russo, S., Scotto di Carlo, F., Maurizi, A., Fortunato, G., Teti, A., Licastro, D., Settembre, C., Mello, T., & Gianfrancesco, F. (2023) · Bone Research · doi:10.1038/s41413-023-00250-3 · Cited by 11
Metadata
- Authors
- Ralston, S. H., Corral-Gudino, L., Cooper, C., Francis, R. M., Fraser, W. D., Gennari, L., Guañabens, N., Javaid, M. K., Layfield, R., O'Neill, T. W., Russell, R. G. G., Stone, M. D., Simpson, K., Wilkinson, D., Wills, R., Zillikens, M. C., & Tuck, S. P.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-02-25
- Volume
- 34
- Issue
- 4
- Pages
- 579-604
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2907719236
- Cited by
- 225
- References
- 8
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- International Osteoporosis Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.